United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - deferoxamine mesylate (unii: v9tko7eo6k) (deferoxamine - unii:j06y7mxw4d) - deferoxamine mesylate 500 mg - desferal is indicated as an adjunct to standard measures for the treatment of acute iron intoxication. desferal is indicated for the treatment of transfusional iron overload in patients with chronic anemia. desferal is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). desferal is contraindicated in patients with: - a history of a hypersensitivity reaction to deferoxamine or any of its inactive ingredients [see description (11)] . reactions have included anaphylaxis [see warnings and precautions (5.1)] . - severe renal disease or anuria since the drug and the iron chelate are excreted primarily by the kidney [see warnings and precautions (5.3)] . risk summary there are no available data on desferal use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriages or adverse maternal or fetal outcomes. in animal reproduction studies subcutaneous administration of deferoxamine to pregnan

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - desferrioxamine mesilate - powder for solution for injection - 2gram

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - desferrioxamine mesylate -

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - deferoxamine mesilate 500mg - powder for injection - 500 mg - active: deferoxamine mesilate 500mg - monotherapy iron chelation treatment for chronic iron overload, e.g. · transfusional haemosiderosis, as seen in thalassaemia major, sideroblastic anaemia, autoimmune haemolytic anaemia, and other chronic anaemias. · idiopathic (primary) haemochromatosis in patients in whom concomitant disorders (e.g. severe anaemia, cardiac disease, hypoproteinaemia) preclude phlebotomy. · iron overload associated with porphyria cutanea tarda in patients unable to tolerate phlebotomy.

Malta - English - Medicines Authority

novartis pharmaceuticals uk limited - deferoxamine 500 mg - powder for solution for injection

Israel - English - Ministry of Health

novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Israel - English - Ministry of Health

novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Israel - English - Ministry of Health

novartis israel ltd - deferoxamine mesylate - powder for solution for inj/inf - deferoxamine mesylate 0.5 g/vial - deferoxamine - treatment of chronic iron overload e.g.: transfusional haemosiderosis especially in thalassaemia major sideroblastic anaemia autoimmune haemolytic anaemia and other chronic anaemias idiopathic (primary) haemochromatosis in patients in whom concomitant disorders ( e.g. severe anaemia cardiac disease hypoproteinaemia) preclude phlebotomy iron overload associated with porphyria cutanea tarda. treatment of acute iron poisoning. treatment of chronic aluminium overload in patients with terminal renal failure (under maintenance dialysis) with: aluminium-related bone disease and/or dialysis encephalopathy and/or aluminium-related anaemia. diagnosis of iron overload.

Ireland - English - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - deferoxamine mesilate - pdr/conc/soln/inj/inf - 500 milligram - iron chelating agents